Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352211
NACRES:
NA.25
Product Name
DC-Chol/DOPE Blend, Avanti Research™ - A Croda Brand
form
powder
packaging
pkg of 1 × 25 mg (790625P-25mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
application(s)
advanced drug delivery
lipid type
cationic lipids
transfection
shipped in
dry ice
storage temp.
−20°C
General description
DC-Cholesterol/Dioleoyl Phosphatidylethanolamine (DOPE) lipid complex comprises the cationic lipid DC-Cholesterol and the neutral helper lipid DOPE.
Application
DC-Chol/DOPE Blend has been used:
- in the preparation of liposomes for ferritin heavy chain 1 (FTH1) siRNA (small interference RNA) transfection studies
- to compare its cytotoxicity tests with ginger derived nanoparticles in colon-26 cells
- as a standard control in MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay to evaluate biocompatibility of ginger derived lipid vesicles
Biochem/physiol Actions
DC-Cholesterol/Dioleoyl Phosphatidylethanolamine (30:70, w/w) helps in transfection of therapeutic small interference RNA (siRNA). DC-Chol/DOPE liposomes are cationic, unilamellar and spherical in nature. It aids in improved condensation of DNA for transfection studies.
Packaging
5 mL Clear Glass Sealed Ampule (790625P-25mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Still not finding the right product?
Explore all of our products under DC-Chol/DOPE Blend
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Meike-Kristin Abraham et al.
Nanotheranostics, 1(2), 154-165 (2017-10-27)
Rationale: Genetic therapy using modified mRNA for specific therapeutic protein expression for disease treatment and vaccination represents a new field of therapeutic and diagnostic medicine. Non-viral vectors transfection using biocompatible nanoliposomes enables safe and efficient delivery of therapeutic mRNA. Objective:
Mingzhen Zhang et al.
Nanomedicine (London, England), 12(16), 1927-1943 (2017-07-01)
To develop novel siRNA delivery system overcoming the limitations of synthetic nanoparticles, such as potential side effects, nonspecificity and economic production for ulcerative colitis therapy. Nanoparticles composed of edible ginger-derived lipid, termed ginger-derived lipid vehicles (GDLVs) were generated from ginger
Mingzhen Zhang et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 24(10), 1783-1796 (2016-08-06)
The use of nanotechnology for drug delivery has shown great promise for improving cancer treatment. However, potential toxicity, hazardous environmental effects, issues with large-scale production, and potential excessive costs are challenges that confront their further clinical applications. Here, we describe
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 790625P-25MG | 04061835189625 |